Design, Development and Evaluation of Instant Release Oral Thin Films of Flunarizine

Asfiya Fatima1, Mamatha Tirunagari2*, Divya Theja Chilekampalli2

1Department of Pharmaceutics, Sultan-ul-Uloom College of Pharmacy, Road No: 3, Banjara Hills, Hyderabad, Telangana State, India
2 Department of Pharmaceutics, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Tarnaka, Secunderabad. Telangana State, India.
*Corresponding author’s E-mail: tmamathasnvpmv@gmail.com

Received: 21-08-2021; Revised: 24-10-2021; Accepted: 03-11-2021; Published on: 15-11-2021.

ABSTRACT

The main objective of the present study was to prepare and evaluate the instant release oral thin films of Flunarizine, in order to enhance the bioavailability of the drug and to provide rapid onset of action thereby improving patient compliance. The instant release oral thin films of Flunarizine were prepared by solvent casting method using film forming polymer like Hydroxypropyl Methylcellulose E-15. The film was evaluated for various physicochemical parameters that include thickness, weight variation, folding endurance, tensile strength, drug content and also H1 blocking action. The design development and also dissolution of drug from the formulated film F1-F9 as the film instantly gets wet by dissolution medium. The drug release for F5 formulations was about 98.1%. The accelerated stability studies for the optimized film formulations F5 were performed that indicates that the formulated in vitro release oral thin films were unaffected after initial and 3 months storage under accelerated conditions.

Keywords: Oral film, Flunarizine, Instant release, Disintegration test.

MATERIALS AND METHODS

Materials

Flunarizine was obtained as a gift sample from Hetero Pharma labs, Hyderabad, India, Hydroxy propyl methyl cellulose, Propylene glycol, Mannitol and Citric acid are obtained from SD Fine Chemicals Ltd., Mumbai, India, Aspartame and Ethanol from Research Lab Fine Chem Industries Ltd., Mumbai, India. All the chemicals used were of analytical grade.

Methods

Calibration curve of Flunarizine

Flunarizine was dissolved in pH 6.8 phosphate buffer to get 100 µg/ml solution. Serial dilutions were made to get 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml of the final solution. The absorbance was measured at 256 nm by using UV spectrophotometer.

Drug-polymer compatibility studies

Drug polymer compatibility studies were carried out using Fourier Transform Infrared Spectrophotometer (FT-IR) (Shimadzu & Perkin Elmer Instruments, USA). The FT-IR absorption spectra of Flunarizine and Flunarizine with polymers (1:1 ratio) was conducted by KBr disc method in the range of 4000-400 cm⁻¹. The spectrum was studied for specific peaks of the drug and polymer.

Calculation of area of film containing single dose of drug Flunarizine

The dose of Flunarizine is 5mg. Therefore, the amount of the Flunarizine drug required in the films is 5 mg.

Diameter of glass ring = 5.9 cm
Radius = Diameter/2 = 5.9/2 = 2.95 cm

As the dose is 5 mg and cutting the pieces in no. of 2.25 cm² films which are present in the whole ring = 27.3/2.25 = 12.1

Each film contains 5 mg of the Flunarizine.

12.1 no. of films contain how much amount of drug? = 12.1 X 5 = 60.5 mg

The amount of drug added during preparation is equal to 60.5 mg, which is meant to be poured into one glass ring of diameter 5.9 cm.

Therefore, the amount of Flunarizine in each film is 5 mg

Development of formulation:

General considerations for formulation

A distinctive composition of oral instant release thin film includes:

- Active ingredients (5-30% W/W), Polymer (40% W/W), Plasticizer (5-20% W/W), Sweetening agent (2-6% W/W), Surfactant (q.s.), Saliva stimulating agent (3-6% W/W), Colors, Fillers, Flavors (q.s.). Potent and small molecular weight drugs are very good candidates for development of fast dissolving oral films formulation.6

Preparation of blank films for preliminary screening of components

Selection of a polymer based on its nature and concentration are important considerations for successful development of fast dissolving film. HPMC E-15 was used as a film former for the present research. Blank formulations were prepared by measuring different composition of polymer (200, 300, 400 and 500 mg) and dissolved in a suitable measured solvent. The polymer is soaked in solvent for a half an hour to obtain a homogeneous solution. The homogeneous solution is casted on a glass plate and allowed to dry at room temperature or put under 45 °C for 2 hr in a hot air oven. The films were then carefully removed and imperfections were found. For further evaluation, films that were transparent and bubble free were chosen. The 2.25 cm² films (1.25 X 1.25) were cut, draped in aluminum foil and then placed in desiccator.

Method of preparation of drug (Flunarizine) loaded oral thin films

The oral thin films are prepared by solvent casting method. Polymer solution was prepared by dissolving weighed quantity of polymer (HPMC E-15) in required quantity of ethanol, soaked for half an hour to swell. Polymeric solution is then agitated for half-an-hour on a magnetic stirrer to obtain a uniform dispersion. Flunarizine is added to the polymer solution with continuous stirring for 5-10 minutes. Aspartame, Mannitol, Citric acid and Propylene glycol were added with remaining quantity of ethanol to the drug polymer solution and mixed for half an hour. The solution was then kept aside in undisturbed condition for the removal of air bubbles. The bubble-free solution was casted in 27.3 cm² region containing the glass ring on the platform. The films are either dried for 24 hr at room temperature or put under 45 °C for 2 hr in a hot air oven. The films were then carefully removed and imperfections were found. For further evaluation, films that were transparent and bubble free were chosen. The 2.25 cm² films (1.25 X 1.25) were cut, draped in aluminum foil and then placed in desiccator.

Table 1: Composition of various oral thin film formulations of Flunarizine

<table>
<thead>
<tr>
<th>S. No</th>
<th>Components (mg/film)</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Drug (Flunarizine)*</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>2.</td>
<td>Polymer (HPMC E-15)*</td>
<td>100</td>
<td>200</td>
<td>300</td>
<td>400</td>
<td>500</td>
<td>600</td>
<td>700</td>
<td>800</td>
<td>900</td>
</tr>
<tr>
<td>5.</td>
<td>Plasticizer (Propylene glycol) ** (ml)</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
</tr>
<tr>
<td>7.</td>
<td>Saliva stimulating agent (citric acid)*</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

*= Expressed as % w/w

**= Expressed as % w/v of the polymer
Evaluation of instant release oral thin films

Morphological properties

Instant release oral thin films were inspected physically for their transparency and air bubble. Each film was checked properly for its appearance, thickness, shape and size.

Thickness of film

Uniformity in thickness of the film is directly related to the accuracy of dose in the film. The thickness of the film was measured by micrometer at three different places and average of three values are calculated.

Weight Variation

From each film formulation three films of 2.25 cm² size were cut at random. Individually films were weighed on electronic balance and the mean weight for every batch was calculated.

Folding Endurance

This test ensures the tensile strength of the film and was checked by visual inspection. This was measured by repeatedly folding. The number of times the film is folded without breaking at the same place gives the folding endurance value.

Surface pH

The surface pH of the film was determined, since an acidic or alkaline pH may cause irritation. The pH of the film is calculated by moistening the film with 0.5 ml distilled water, kept for 1hr. The pH was measured by bringing pH electrode in make contact with surface of the film and allow it equilibrate for 1 minute. The averages of three values were determined.

Drug content uniformity

Content uniformity is determined by estimating the content of the drug in individual films. Limit regarding to content uniformity is 85-115%.

This is calculated by dissolving known weight of film in 100 ml of simulated saliva of pH 6.8 for 30 min by continuous shaking. Then, spectrophotometrically, the concentration of the drug was analyzed at λmax 256 nm. On average, five films have been taken. The concentration was measured with the normal calibration curve of Flunarizine.

In vitro Disintegration method

The disintegration time is the time when the film starts to disintegrate or break. This was determined visually by placing the oral film into the petridish containing 25 ml of pH 6.8 phosphate buffer with swirling for every 10 sec.

In vitro Dissolution test

The dissolution test was performed by USP type II paddle dissolution apparatus. Drug loaded films (5 mg) was cut into 2.25 cm² and placed in dissolution media consisting of 900 ml freshly deionized simulated saliva of pH 6.8 at 37 ± 1°C stirred at 75 rpm. At predetermined intervals 5 ml of sample were withdrawn and replaced with fresh medium. Blank film solution is used as blank while measuring absorbance. The solution is filtered using Whatmann filter paper, diluted suitably and the absorbance was measured at 256 nm by UV spectrophotometer.

Stability studies

Instant release oral thin films of formulation F5 were placed at stability testing conditions of temperature 40 ± 2°C and relative humidity of 75 ± 5%. Initial and third month study was carried out for the films. Films were wrapped in butter paper along with aluminum foil and then placed in an aluminum pouch which is heat sealed at the end. These instant release oral thin films were evaluated for their appearance, disintegration test, and in vitro dissolution test after storage of the films.

RESULTS AND DISCUSSION

In this study an attempt has been made to formulate and evaluate instant release oral thin films of Flunarizine.

Calibration curve of Flunarizine

The calibration curve of Flunarizine has a regression coefficient of 0.9983 and is shown in figure 2.
Drug-polymer compatibility studies
The peaks that are specific to the drug are observed both in pure drug and mixture FTIR spectra. Hence it was confirmed that drug and excipients are compatible. FTIR spectra of mixture is shown in figure 3.

Evaluation test for instant release oral thin film formulations

Morphological properties
The discovery is normal by visual examination of films and by touch and even feel, it clarified that the oral thin films are automatically released and have a smooth and elegant surface, i.e. they have a transparent, smooth surface, figure 4.

Thickness of the films
The thickness of oral thin films was observed to be between 0.11 mm to 0.20 mm. The thickness was increased as the polymer quantity is more from formulation F1 to F9. These thickness values are depicted in table 2.

Folding Endurance
The folding endurance is found to be between 6 to 21 and is shown in table 2. The films were found to be flexible.

Surface pH value
The surface pH value of instant release oral thin films is found to be in the range of 6.5-6.8 which is similar to oral cavity pH.

Drug content uniformity
The drug content uniformity is performed by taking three instant release oral thin films in each formulation trial and the average drug content was calculated. The results of average drug content of all the films were summarized in table 2. All formulations drug content was found to be uniform hence it was confirmed that the method of preparation is most suitable.

In vitro disintegration test
The disintegration time of the prepared instant release oral thin films were in the range of 15 sec to 35 sec. The results of average disintegration time of all the films were summarized in the table 2. The least disintegration time is found to be for formulation F5 compared to other formulations. All the formulations disintegration time was found to be below one minute, indicating the correct formulation of all films.

Table 2: Evaluation data for instant release oral thin films of Flunarizine

<table>
<thead>
<tr>
<th>Formulation Code</th>
<th>Appearance</th>
<th>Folding Endurance</th>
<th>Thickness (mm)</th>
<th>Surface pH</th>
<th>% Drug Content</th>
<th>Disintegration time (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>Film is thick and not clear</td>
<td>12</td>
<td>0.11</td>
<td>6.8</td>
<td>94</td>
<td>29</td>
</tr>
<tr>
<td>F2</td>
<td>Film is smooth and clear</td>
<td>15</td>
<td>0.13</td>
<td>6.6</td>
<td>95</td>
<td>25</td>
</tr>
<tr>
<td>F3</td>
<td>Film is smooth and clear</td>
<td>17</td>
<td>0.15</td>
<td>6.6</td>
<td>93</td>
<td>23</td>
</tr>
<tr>
<td>F4</td>
<td>Film is clear but not have strength</td>
<td>06</td>
<td>0.16</td>
<td>6.6</td>
<td>95</td>
<td>28</td>
</tr>
<tr>
<td>F5</td>
<td>Film is smooth and clear</td>
<td>21</td>
<td>0.16</td>
<td>6.5</td>
<td>98</td>
<td>15</td>
</tr>
<tr>
<td>F6</td>
<td>Film does not have strength</td>
<td>12</td>
<td>0.17</td>
<td>6.7</td>
<td>96</td>
<td>21</td>
</tr>
<tr>
<td>F7</td>
<td>Film is clear but thick</td>
<td>14</td>
<td>0.18</td>
<td>6.6</td>
<td>94</td>
<td>24</td>
</tr>
<tr>
<td>F8</td>
<td>Film is clear but thick</td>
<td>08</td>
<td>0.19</td>
<td>6.8</td>
<td>91</td>
<td>35</td>
</tr>
<tr>
<td>F9</td>
<td>Film is smooth and clear, thick</td>
<td>13</td>
<td>0.20</td>
<td>6.6</td>
<td>93</td>
<td>30</td>
</tr>
</tbody>
</table>
In vitro dissolution studies

The in vitro dissolution results were presented in table 3. In all the formulations more than 80 percent drug release was observed within 30 minutes. Compared to all formulations, in formulation F5, more than 90 percent of the drug release is observed in 10 minutes. As the disintegration time is also less for this formulation it was selected as best formulation among all and stability test was conducted for the same.

Table 3: In vitro drug release studies from F1 to F9

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>42.15</td>
<td>48.10</td>
<td>62.21</td>
<td>68.35</td>
<td>85.41</td>
<td>79.10</td>
<td>80.21</td>
<td>74.62</td>
<td>51.95</td>
</tr>
<tr>
<td>10</td>
<td>58.45</td>
<td>62.19</td>
<td>75.28</td>
<td>74.76</td>
<td>93.24</td>
<td>84.76</td>
<td>88.82</td>
<td>79.72</td>
<td>59.14</td>
</tr>
<tr>
<td>15</td>
<td>69.72</td>
<td>73.76</td>
<td>86.76</td>
<td>84.49</td>
<td>95.29</td>
<td>91.19</td>
<td>91.17</td>
<td>83.25</td>
<td>74.86</td>
</tr>
<tr>
<td>20</td>
<td>76.61</td>
<td>82.42</td>
<td>93.65</td>
<td>92.36</td>
<td>97.38</td>
<td>92.82</td>
<td>92.25</td>
<td>80.46</td>
<td>81.26</td>
</tr>
<tr>
<td>30</td>
<td>84.31</td>
<td>91.35</td>
<td>95.16</td>
<td>91.27</td>
<td>97.76</td>
<td>92.76</td>
<td>94.85</td>
<td>89.12</td>
<td>93.16</td>
</tr>
</tbody>
</table>

Stability studies

Stability studies for the optimized film formulation F5 was performed at 40 ± 2°C/ 75 ± 5% RH. The films were evaluated for appearance, disintegration time, percent drug release and results are shown in table 4. After stability testing not much difference is observed in appearance, disintegration time and percent drug release hence it was confirmed that the F5 formulation is stable.

Table 4: Stability studies of F5 formulation at 40 ± 2°C/ 75 ± 5% RH

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Time</th>
<th>Appearance</th>
<th>Disintegration time (sec)</th>
<th>Cumulative percentage drug release</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Initial (0 month)</td>
<td>Transparent and acceptable</td>
<td>16.5</td>
<td>95.6</td>
</tr>
<tr>
<td>2</td>
<td>3 months</td>
<td>Transparent and acceptable</td>
<td>21</td>
<td>97.1</td>
</tr>
</tbody>
</table>
CONCLUSION

The instant release oral thin films of Flunarizine were formulated by solvent casting method. Drug excipient compatibility studies determine that drug and excipient are compatible to each other. HPMC E-15 polymer was selected and different concentrations of formulation were formulated from F1 to F9 and assessed for various evaluation parameters. The films were thin and as the concentration increases the thickness also increases. All the films prepared were found to be flexible and transparent. Disintegration time was less for formulation F5. In vitro dissolution tests for formulations F1 to F9 were performed by USP type II paddle dissolution apparatus and the results revealed that the formulation F5 shows high dissolution profile and also the drug content was 98%. The accelerated stability studies for the optimized film F5 formulations were performed and were unaffected after initial and 3 months storage under accelerated conditions.

REFERENCES


Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any question relates to this article, please reach us at: editor@globalresearchonline.net
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ibpsrr@rediffmail.com